Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

August 01, 2014
S1207
Breast Cancer
Alexander Hantel, MD

Naperville, Plainfield

Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.

This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

Sponsor: SWOG (formerly the Southwest Oncology Group)

http://clinicaltrials.gov/ct2/show/record/NCT01674140?term=01674140&rank=1

  • Must have invasive breast carcinoma with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative human epidermal growth factor receptor (HER)2
  • Must not have inflammatory or metastatic breast cancer (stage IV disease)
  • Must be high risk 
  • Must not have any grade III/IV cardiac disease, uncontrolled diabetes, or hepatitis

10-12 years

Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6050
630-646-6110
630-646-6075